Replication licensing is an attractive anti-cancer target as normal cells possess a “licensing checkpoint” that many cancer cells lack, most likely because it requires the activity of proteins such as p53, Rb, and p21Cip1, which are often lost in cancer. Here, CDKN1A is linked to cancer.